In this issue:
No early signs of cardiovascular risk in paediatric AD
Stapokibart is safe and efficacious for adolescents with moderate-to-severe AD
High burden of respiratory comorbidity in people with AD
Colloidal oatmeal moisturisers are an effective adjunctive therapy
ARCADIA: long-term nemolizumab elicits meaningful improvements in AD
No cumulative increased safety risks with long-term upadacitinib
Nemolizumab rapidly alleviates itch in AD and prurigo nodularis
Anti-IL-13 antibodies are effective for AD head and neck lesions
Upadacitinib has a more favourable ocular safety profile versus dupilumab
Can children receiving dupilumab safely receive live vaccines?
Please login below to download this issue (PDF)